ICRF is proud to note that many of its awardees have been and continue to be involved with major cancer research breakthroughs:
• Velcade - a drug used to treat multiple myeloma, a cancer of the bone marrow, was developed based on the research of ICRF Professors and Nobel Prize winners, Drs. Avram Hershko and Aaron Ciechanover, Technion,
Israel Institute of Technology.
• Gleevec - the first drug to directly target cancer cells, was developed based on the research work of ICRF awardee, Dr. Eli Canaani, Weizmann Institute of Science.
• Doxil - the first drug encapsulated in a liposome (or microscopic fat bubble) for direct delivery to a tumor site, was developed by ICRF awardee, Dr. Alberto Gabizon, Shaare Zedek Medical Center.
• The p53 Gene - originally thought to cause cancer, was correctly identified as a tumor suppressor, and its role in the majority of human cancers further elucidated by ICRF awardees, Drs. Moshe Oren and Varda Rotter, Weizmann Institute of Science.
• DNA Methylation - is a molecular process that turns genes on and off. Pioneering work in this area was performed by ICRF Professor and Israel Prize winner, Dr. Howard Cedar, Hebrew University/Hadassah Medical School.
• The RAD51 Gene - The discovery that a minor mutation in this gene increases the risk of breast cancer in women with the BRCA2 gene mutation was made by ICRF awardee Dr. Ephrat Levy-Lahad, Shaare Zedek Medical Center.
• A Novel Bone Marrow Transplant Technique - to greatly expand the donor pool for leukemia treatment, was developed by ICRF awardee,Dr.Yair Reisner,Weizmann Institute of Science.